Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Chembio's Ethiopia order factored in estimates, says Benchmark » 14:18
07/22/21
07/22
14:18
07/22/21
14:18
CEMI

Chembio Diagnostics

$5.80 /

+0.465 (+8.72%)

After Chembio Diagnostics…

After Chembio Diagnostics announced the receipt of a $4M purchase order for HIV 1/2 STAT-PAK tests to be sent to Ethiopia, Benchmark analyst Bruce Jackson said the deal appears to be a continuation of a three-year contract granted in 2018. This was already assumed as part of his estimates for 2021 and 2022, which leaves him making no change to his estimates or Hold rating for Chembio, said Jackson.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$5.80 /

+0.465 (+8.72%)

CEMI Chembio Diagnostics
$5.80 /

+0.465 (+8.72%)

07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
CEMI Chembio Diagnostics
$5.80 /

+0.465 (+8.72%)

CEMI Chembio Diagnostics
$5.80 /

+0.465 (+8.72%)

CEMI Chembio Diagnostics
$5.80 /

+0.465 (+8.72%)

Hot Stocks
Chembio Diagnostics announces $4M HIV test purchase order » 12:52
07/22/21
07/22
12:52
07/22/21
12:52
CEMI

Chembio Diagnostics

$4.68 /

-0.655 (-12.28%)

Chembio Diagnostics…

Chembio Diagnostics announced its receipt of a $4M purchase order from the Partnership for Supply Chain Management, or PFSCM, supported by The Global Fund, for the purchase of Chembio's HIV 1/2 STAT-PAK Assay for shipment to Ethiopia into early 2022. "Chembio's delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control," the company said.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.68 /

-0.655 (-12.28%)

CEMI Chembio Diagnostics
$4.68 /

-0.655 (-12.28%)

07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
CEMI Chembio Diagnostics
$4.68 /

-0.655 (-12.28%)

CEMI Chembio Diagnostics
$4.68 /

-0.655 (-12.28%)

CEMI Chembio Diagnostics
$4.68 /

-0.655 (-12.28%)

Downgrade
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive' » 14:35
07/21/21
07/21
14:35
07/21/21
14:35
CEMI

Chembio Diagnostics

$6.56 /

+4.495 (+217.68%)

As previously reported,…

As previously reported, Colliers analyst Kyle Bauser downgraded Chembio Diagnostics to Neutral from Buy. He views the current share price as "too aggressive" given the company's below average growth rate, lack of near-term profitability and what he calls "disappointing execution over the past several quarters." Shares of Chembio Diagnostics are up $4.22, or 205%, to $6.28 in afternoon trading.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$6.56 /

+4.495 (+217.68%)

CEMI Chembio Diagnostics
$6.56 /

+4.495 (+217.68%)

07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
CEMI Chembio Diagnostics
$6.56 /

+4.495 (+217.68%)

CEMI Chembio Diagnostics
$6.56 /

+4.495 (+217.68%)

CEMI Chembio Diagnostics
$6.56 /

+4.495 (+217.68%)

Downgrade
Chembio Diagnostics downgraded to Neutral from Buy at Colliers » 14:32
07/21/21
07/21
14:32
07/21/21
14:32
CEMI

Chembio Diagnostics

$6.32 /

+4.255 (+206.05%)

Colliers analyst Kyle…

Colliers analyst Kyle Bauser downgraded Chembio Diagnostics to Neutral from Buy.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$6.32 /

+4.255 (+206.05%)

CEMI Chembio Diagnostics
$6.32 /

+4.255 (+206.05%)

12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
CEMI Chembio Diagnostics
$6.32 /

+4.255 (+206.05%)

CEMI Chembio Diagnostics
$6.32 /

+4.255 (+206.05%)

CEMI Chembio Diagnostics
$6.32 /

+4.255 (+206.05%)

On The Fly
Fly Intel: Pre-market Movers » 09:02
07/21/21
07/21
09:02
07/21/21
09:02
CEMI

Chembio Diagnostics

$2.07 /

-0.425 (-17.07%)

, JNJ

Johnson & Johnson

$168.60 /

+1.75 (+1.05%)

, KO

Coca-Cola

$55.81 /

+0.08 (+0.14%)

, VZ

Verizon

$55.58 /

-0.27 (-0.48%)

, ANTM

Anthem

$390.00 /

+5.68 (+1.48%)

, STX

Seagate

$85.49 /

+1.24 (+1.47%)

, IPG

Interpublic Group

$31.27 /

+0.375 (+1.21%)

, HOG

Harley-Davidson

$43.92 /

+2 (+4.77%)

, SNBR

Sleep Number

$112.46 /

+5.9 (+5.54%)

, NFLX

Netflix

$531.53 /

+0.33 (+0.06%)

, STAF

Staffing 360 Solutions

$3.75 /

+0.52 (+16.10%)

, MRNA

Moderna

$307.50 /

-6.31 (-2.01%)

, LUMO

Lumos Pharma

$9.50 /

-0.05 (-0.52%)

, CMG

Chipotle

$1,577.92 /

+31.88 (+2.06%)

Check out this morning's…

ShowHide Related Items >><<
VZ Verizon
$55.58 /

-0.27 (-0.48%)

STX Seagate
$85.49 /

+1.24 (+1.47%)

STAF Staffing 360 Solutions
$3.75 /

+0.52 (+16.10%)

SNBR Sleep Number
$112.46 /

+5.9 (+5.54%)

NFLX Netflix
$531.53 /

+0.33 (+0.06%)

MRNA Moderna
$307.50 /

-6.31 (-2.01%)

LUMO Lumos Pharma
$9.50 /

-0.05 (-0.52%)

KO Coca-Cola
$55.81 /

+0.08 (+0.14%)

JNJ Johnson & Johnson
$168.60 /

+1.75 (+1.05%)

IPG Interpublic Group
$31.27 /

+0.375 (+1.21%)

HOG Harley-Davidson
$43.92 /

+2 (+4.77%)

CMG Chipotle
$1,577.92 /

+31.88 (+2.06%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

ANTM Anthem
$390.00 /

+5.68 (+1.48%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
JNJ Johnson & Johnson
$168.60 /

+1.75 (+1.05%)

07/08/21 Stifel
Vor Biopharma, Janssen collaboration benefits both parties, says Stifel
07/02/21 Cantor Fitzgerald
J&J vaccine shows 'strong' activist against Delta, says Cantor Fitzgerald
06/28/21 Cantor Fitzgerald
J&J opioid settlement removes share overhang, says Cantor Fitzgerald
06/22/21 JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
KO Coca-Cola
$55.81 /

+0.08 (+0.14%)

07/16/21 Jefferies
Coca-Cola price target upped to $59 at Jefferies ahead of expected guidance hike
07/12/21 Deutsche Bank
Coca-Cola price target raised to $58 from $57 at Deutsche Bank
06/17/21 Argus
Coca-Cola price target raised to $63 from $60 at Argus
06/15/21 Credit Suisse
Coca-Cola price target raised to $62 from $60 at Credit Suisse
VZ Verizon
$55.58 /

-0.27 (-0.48%)

07/07/21 Tigress Financial
Verizon shares have upside to $67 in 12 months, says Tigress Financial
06/25/21
Fly Intel: Top five analyst initiations
06/25/21 Redburn
Redburn puts Sell ratings on AT&T and Verizon, Buy on Comcast
06/25/21 Redburn
Verizon initiated with a Sell at Redburn
ANTM Anthem
$390.00 /

+5.68 (+1.48%)

07/09/21 Seaport Global
Seaport Global initiates five in Managed Care with three Buys
07/09/21 Seaport Global
Anthem initiated with a Buy at Seaport Global
07/02/21 Mizuho
CVS Health came out on top in PBM checks, says Mizuho
06/17/21 Stephens
Supreme Court ruling removes overhang on ACA levered stocks, says Stephens
STX Seagate
$85.49 /

+1.24 (+1.47%)

07/21/21 Summit Insights
Seagate downgraded to Hold on Chia crypto risk Summit Insights
07/21/21 Summit Insights
Seagate downgraded to Hold from Buy at Summit Insights
07/16/21 Wedbush
Seagate price target raised to $85 from $70 at Wedbush
07/15/21 Mizuho
Seagate price target raised to $95 from $88 at Mizuho
IPG Interpublic Group
$31.27 /

+0.375 (+1.21%)

07/02/21 Barclays
Interpublic Group price target raised to EUR 36.50 from EUR 36 at Barclays
04/29/21 Wells Fargo
Interpublic Group price target raised to $36 from $26 at Wells Fargo
04/29/21 BMO Capital
Interpublic Group price target raised to $34 from $30 at BMO Capital
04/22/21 BMO Capital
Interpublic Group downgraded to Market Perform from Outperform at BMO Capital
HOG Harley-Davidson
$43.92 /

+2 (+4.77%)

07/02/21 Wedbush
Harley-Davidson checks show Q2 retail sales up versus 2019, says Wedbush
07/01/21 Baird
Baird remains bullish on Harley-Davidson's Hardwire 2025 plan
06/21/21 BMO Capital
BMO Capital positive on Harley-Davidson given management changes
06/04/21 Wedbush
Harley-Davidson price target raised to $60 from $55 at Wedbush
SNBR Sleep Number
$112.46 /

+5.9 (+5.54%)

07/21/21 Piper Sandler
Sleep Number price target lowered to $135 from $165 at Piper Sandler
02/18/21
Fly Intel: Top five analyst upgrades
02/18/21 Wedbush
Sleep Number price target raised to $130 from $120 at Wedbush
02/18/21 Piper Sandler
Sleep Number price target raised to $165 from $108 at Piper Sandler
NFLX Netflix
$531.53 /

+0.33 (+0.06%)

07/21/21 Evercore ISI
Evercore reiterates Outperform on Netflix after Q2 'clearing event'
07/21/21 Wedbush
Netflix Q3 guidance 'uninspiring,' games a misstep, says Wedbush
07/21/21 Credit Suisse
Netflix price target raised to $643 from $586 at Credit Suisse
07/21/21 UBS
Netflix Q2 likely the low point for sub growth, says UBS
STAF Staffing 360 Solutions
$3.75 /

+0.52 (+16.10%)

05/19/21 Greenridge
Staffing 360 Solutions price target lowered to $2.50 from $3.50 at Greenridge
MRNA Moderna
$307.50 /

-6.31 (-2.01%)

07/15/21 Jefferies
Moderna price target raised to $250 from $170 at Jefferies
07/07/21 Piper Sandler
Moderna could 'revolutionize' flu vaccine market, says Piper Sandler
06/29/21 Wells Fargo
Moderna vaccine demonstrates activity against key variants, says Wells Fargo
06/29/21 Goldman Sachs
Goldman continues to anticipate clinical need for booster vaccines
LUMO Lumos Pharma
$9.50 /

-0.05 (-0.52%)

07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
04/13/21 JonesTrading
Lumos Pharma initiated with a Buy at JonesTrading
03/11/21 Stifel
Lumos Pharma upgraded to Buy from Hold at Stifel
12/03/20
Fly Intel: Top five analyst initiations
CMG Chipotle
$1,577.92 /

+31.88 (+2.06%)

07/21/21 Evercore ISI
Chipotle price target raised to $1,950 from $1,800 at Evercore ISI
07/21/21 BTIG
Chipotle price target raised to $1,850 from $1,725 at BTIG
07/21/21 Truist
Chipotle price target raised to $1,800 from $1,750 at Truist
07/21/21 Cowen
Chipotle price target raised to $2080 from $1850 at Cowen
VZ Verizon
$55.58 /

-0.27 (-0.48%)

STX Seagate
$85.49 /

+1.24 (+1.47%)

STAF Staffing 360 Solutions
$3.75 /

+0.52 (+16.10%)

SNBR Sleep Number
$112.46 /

+5.9 (+5.54%)

NFLX Netflix
$531.53 /

+0.33 (+0.06%)

MRNA Moderna
$307.50 /

-6.31 (-2.01%)

LUMO Lumos Pharma
$9.50 /

-0.05 (-0.52%)

KO Coca-Cola
$55.81 /

+0.08 (+0.14%)

JNJ Johnson & Johnson
$168.60 /

+1.75 (+1.05%)

IPG Interpublic Group
$31.27 /

+0.375 (+1.21%)

HOG Harley-Davidson
$43.92 /

+2 (+4.77%)

CMG Chipotle
$1,577.92 /

+31.88 (+2.06%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

ANTM Anthem
$390.00 /

+5.68 (+1.48%)

  • 04
    Mar
  • 10
    Feb
  • 24
    Dec
VZ Verizon
$55.58 /

-0.27 (-0.48%)

STX Seagate
$85.49 /

+1.24 (+1.47%)

NFLX Netflix
$531.53 /

+0.33 (+0.06%)

MRNA Moderna
$307.50 /

-6.31 (-2.01%)

KO Coca-Cola
$55.81 /

+0.08 (+0.14%)

JNJ Johnson & Johnson
$168.60 /

+1.75 (+1.05%)

IPG Interpublic Group
$31.27 /

+0.375 (+1.21%)

HOG Harley-Davidson
$43.92 /

+2 (+4.77%)

CMG Chipotle
$1,577.92 /

+31.88 (+2.06%)

ANTM Anthem
$390.00 /

+5.68 (+1.48%)

VZ Verizon
$55.58 /

-0.27 (-0.48%)

STX Seagate
$85.49 /

+1.24 (+1.47%)

STAF Staffing 360 Solutions
$3.75 /

+0.52 (+16.10%)

SNBR Sleep Number
$112.46 /

+5.9 (+5.54%)

NFLX Netflix
$531.53 /

+0.33 (+0.06%)

MRNA Moderna
$307.50 /

-6.31 (-2.01%)

KO Coca-Cola
$55.81 /

+0.08 (+0.14%)

JNJ Johnson & Johnson
$168.60 /

+1.75 (+1.05%)

IPG Interpublic Group
$31.27 /

+0.375 (+1.21%)

HOG Harley-Davidson
$43.92 /

+2 (+4.77%)

CMG Chipotle
$1,577.92 /

+31.88 (+2.06%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

ANTM Anthem
$390.00 /

+5.68 (+1.48%)

VZ Verizon
$55.58 /

-0.27 (-0.48%)

STX Seagate
$85.49 /

+1.24 (+1.47%)

NFLX Netflix
$531.53 /

+0.33 (+0.06%)

MRNA Moderna
$307.50 /

-6.31 (-2.01%)

KO Coca-Cola
$55.81 /

+0.08 (+0.14%)

JNJ Johnson & Johnson
$168.60 /

+1.75 (+1.05%)

IPG Interpublic Group
$31.27 /

+0.375 (+1.21%)

HOG Harley-Davidson
$43.92 /

+2 (+4.77%)

CMG Chipotle
$1,577.92 /

+31.88 (+2.06%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

ANTM Anthem
$390.00 /

+5.68 (+1.48%)

Hot Stocks
Chembio reports $28.3M purchase order for DPP SARS-CoV-2 antigen tests in Brazil » 07:54
07/21/21
07/21
07:54
07/21/21
07:54
CEMI

Chembio Diagnostics

$2.07 /

-0.425 (-17.07%)

Chembio Diagnostics…

Chembio Diagnostics announced its receipt of a $28.3M purchase order from Bio-Manguinhos for the purchase of Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil's Ministry of Health in addressing the COVID-19 pandemic. "Chembio's delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control. Bio-Manguinhos, a subsidiary of the Oswaldo Cruz Foundation, is responsible for the development and production of vaccines, diagnostics, and biopharmaceuticals, primarily to meet demands of Brazil's national public health system. Chembio has a long-standing relationship with Bio-Manguinhos, having supplied multiple products for point-of-care detection of COVID-19 antibodies, HIV, and other infectious diseases. Bio-Manguinhos received regulatory approval from Agencia Nacional de Vigilancia Sanitaria in March 2021, following ANVISA approval of the test for Chembio's Brazilian subsidiary in November 2020," the company stated. In pre-market trading, Chembio Diagnostics shares have risen $2.17, or 105%, to $4.23.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

CEMI Chembio Diagnostics
$2.07 /

-0.425 (-17.07%)

Hot Stocks
Chembio Diagnostics announces at the market offering for up to $60M in stock » 07:26
07/20/21
07/20
07:26
07/20/21
07:26
CEMI

Chembio Diagnostics

$2.49 /

+0.0698 (+2.88%)

In a regulatory filing,…

In a regulatory filing, Chembio Diagnostics announced that on July 19, 2021, the company entered into an at the market offering agreement, or the ATM agreement, with Craig-Hallum Capital Group, pursuant to which it may sell from time to time, at its option, up to an aggregate of $60M of shares of common stock through Craig-Hallum as sales agent. "We currently anticipate that the net proceeds from any sale of Shares under the ATM Agreement will be used for general corporate purposes, which may include, but are not limited to, working capital and capital expenditures. We cannot provide any assurances that we will issue any Shares pursuant to the ATM Agreement," the filing stated.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

Earnings
Chembio Diagnostics sees Q2 revenue $6.4M, consensus $8.53M » 07:24
07/20/21
07/20
07:24
07/20/21
07:24
CEMI

Chembio Diagnostics

$2.49 /

+0.0698 (+2.88%)

In a regulatory filing…

In a regulatory filing last night, Chembio Diagnostics said: "We estimate that our total revenues for the three months ended June 30, 2021 were $6.4M. Our revenues during the three months ended June 30, 2021 did not meet our expectations, and the shortfall in our revenues has been a principal cause of our current limited cash and cash-equivalents position... In June 2021 the FDA notified us that it was again declining to review the DPP SARS-CoV-2 Antigen System based on the FDA's then-effective prioritization guidance, under which review of the test system was not a priority because of the anticipated resources needed by the FDA to continue review of our EUA request, the volume of EUA requests the FDA had received, and a variety of other factors, such as the public health need for the test system, the extent to which the test system would serve a significant unmet medical need, and the availability and adequacy of the information concerning the likelihood that the test system would be safe and effective in diagnosing the disease. Our clinical trials and the related timeline and achievement of related milestones under the Initial Grant had been delayed by factors including (a) the evolving U.S. populations with low COVID-19 positivity rates triggered by vaccination rollouts, (b) the impact of those evolving populations on the rate of enrolling subjects, and (c) the absence of guidance from the FDA regarding how to treat low positivity rates within a clinical study. The effects of the changing population were reflected in our clinical results and created complexities in the data set submitted for the FDA review in connection with the EUA application for the DPP SARS-CoV-2 Antigen System. In June 2021 BARDA extended the Initial Grant's contract period of performance at no additional cost to BARDA, in order to provide us the opportunity to submit a new EUA to the FDA to address the FDA's additional priorities and incorporate additional data collected from international populations with higher positivity rates. Subsequent to our EUA submission in May 2021, the FDA issued guidance permitting the inclusion in clinical data of foreign-sourced samples from regions with high COVID-19 positivity rates. We are in the process of collecting such samples in order to address the complexities in our data set that we believe resulted in the FDA's decision to deprioritize our second EUA application. We then intend to incorporate the collected samples in our clinical data for a new EUA application for the DPP SARS-CoV-2 Antigen System. There can be no assurance that the FDA will prioritize the review of our new EUA application if made or that, if the FDA does determine to review the new EUA application, the submitted materials will satisfy the performance criteria and other FDA review standards and requirements then being considered and applied by the FDA."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

CEMI Chembio Diagnostics
$2.49 /

+0.0698 (+2.88%)

Over a month ago
Earnings
Chembio Diagnostics reports Q1 EPS (22c), consensus (32c) » 17:29
05/06/21
05/06
17:29
05/06/21
17:29
CEMI

Chembio Diagnostics

$3.53 /

-0.09 (-2.49%)

Reports Q1 revenue…

Reports Q1 revenue $8.72M, consensus $8.19M. "In recent months we have advanced several strategic initiatives focused on leveraging the capabilities of our network of distributors and fully scaled U.S. salesforce across our diversified product portfolio," said Richard Eberly, Chembio's president and CEO. "Commercially, we are seeing good momentum with our SURE CHECK HIV Self-Test via our international channels and our DPP HIV-Syphilis system in the United States."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$3.53 /

-0.09 (-2.49%)

CEMI Chembio Diagnostics
$3.53 /

-0.09 (-2.49%)

12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
06/17/20
Fly Intel: Top five analyst downgrades
CEMI Chembio Diagnostics
$3.53 /

-0.09 (-2.49%)

  • 07
    May
CEMI Chembio Diagnostics
$3.53 /

-0.09 (-2.49%)

CEMI Chembio Diagnostics
$3.53 /

-0.09 (-2.49%)

Options
Chembio Diagnostics options imply 23.3% move in share price post-earnings » 15:19
05/06/21
05/06
15:19
05/06/21
15:19
CEMI

Chembio Diagnostics

$3.48 /

-0.14 (-3.87%)

Pre-earnings options…

Pre-earnings options volume in Chembio Diagnostics is normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 23.3%, or 81c, after results are released. Median move over the past eight quarters is 8.1%.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$3.48 /

-0.14 (-3.87%)

CEMI Chembio Diagnostics
$3.48 /

-0.14 (-3.87%)

12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy at Craig-Hallum
12/03/20 Craig-Hallum
Chembio Diagnostics upgraded to Buy from Hold at Craig-Hallum
11/06/20 Colliers
Chembio Diagnostics upgraded to Buy from Neutral at Colliers
06/17/20
Fly Intel: Top five analyst downgrades
CEMI Chembio Diagnostics
$3.48 /

-0.14 (-3.87%)

  • 07
    May
CEMI Chembio Diagnostics
$3.48 /

-0.14 (-3.87%)

CEMI Chembio Diagnostics
$3.48 /

-0.14 (-3.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.